Skip to main content

Table 1 Demographic data of the participants (N = 300)

From: Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition

Characteristics (n)

CN− (113)

CN+ (36)

MCI− (31)

MCI+ (56)

DEM− (6)

DEM+ (58)

P value

Gender, M/F

46/67

20/16

10/21

17/39

2/4

18/40

> 0.1

Age, years, mean ± SEM

67.32 ± 0.8

74.47 ± 1.0

73.58 ± 0.1

73.23 ± 0.9

75.66 ± 4.3

72.28 ± 1.0

< 0.001*

Education, mean ± SEM

11.39 ± 0.5

12.08 ± 0.8

9.2 ± 0.8

10.16 ± 0.6

6.00 ± 1.7

9.67 ± 0.7

< 0.01*

MMSE, mean ± SEM

26.96 ± 0.2

27.16 ± 0.4

22.93 ± 0.6

21.73 ± 0.4

18.17 ± 3.0

16.59 ± 0.5

< 0.001*

MMSE z, mean ± SEM

0.29 ± 0.1

0.44 ± 0.1

− 0.91 ± 0.2

− 1.54 ± 0.2

− 2.08 ± 0.2

− 3.23 ± 0.2

< 0.001*

CDR (n)

0 (113)

0 (36)

0.5 (31)

0.5 (56)

0.5 (2), 1 (4)

0.5 (17), 1 (41)

< 0.001

ApoE4 status, ε4+/N

20/113

12/36

2/31

33/56

0/6

40/58

< 0.001

PiB (SUVR), mean ± SEM

1.10 ± 0.01

1.62 ± 0.05

1.13 ± 0.01

1.92 ± 0.04

1.10 ± 0.02

2.10 ± 0.05

< 0.001*

  1. CN cognitively normal, MCI mild cognitive impairment, DEM clinically dementia, PiB Pittsburgh compound B, − or +, PiB positivity, SEM standard error of mean, n number of participants, MMSE Mini-Mental State Examination, MMSE z score a revised value of the MMSE score with consideration for age, gender, and education level, CDR Clinical Dementia Rating, ApoE Apolipoprotein E, SUVR standardized uptake value ratio, N total number of participants of each group
  2. *Significance by one-way analysis of variance test (ANOVA)
  3. Significance by chi-squared test